Insider Selling: Loxo Oncology, Inc. (LOXO) Insider Sells $133,327.32 in Stock

Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $86.52, for a total value of $133,327.32. Following the transaction, the insider now owns 1,541 shares of the company’s stock, valued at $133,327.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Naarden Jacob Van also recently made the following trade(s):

  • On Monday, September 18th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $89.20, for a total value of $137,457.20.
  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $89.00, for a total value of $274,298.00.
  • On Monday, August 14th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $73.73, for a total value of $113,617.93.
  • On Tuesday, August 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $73.57, for a total value of $226,742.74.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $87.79 on Friday.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.15). During the same period last year, the business earned ($0.77) earnings per share. research analysts forecast that Loxo Oncology, Inc. will post -4.33 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Loxo Oncology, Inc. (LOXO) Insider Sells $133,327.32 in Stock” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/11/04/insider-selling-loxo-oncology-inc-loxo-insider-sells-133327-32-in-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of LOXO. Lord Abbett & CO. LLC raised its position in shares of Loxo Oncology by 372.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock worth $59,304,000 after acquiring an additional 582,862 shares in the last quarter. FMR LLC raised its position in shares of Loxo Oncology by 12.1% during the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after acquiring an additional 472,814 shares in the last quarter. Marshall Wace North America L.P. acquired a new stake in shares of Loxo Oncology during the 2nd quarter worth about $33,347,000. State Street Corp raised its position in shares of Loxo Oncology by 155.2% during the 1st quarter. State Street Corp now owns 547,017 shares of the biopharmaceutical company’s stock worth $23,019,000 after acquiring an additional 332,696 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Loxo Oncology by 50.2% during the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after acquiring an additional 312,988 shares in the last quarter.

Several equities analysts have recently issued reports on LOXO shares. BidaskClub cut Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. JMP Securities cut Loxo Oncology from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. Cowen and Company reiterated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. BTIG Research reiterated a “buy” rating and issued a $102.00 price objective (up previously from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a research note on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Loxo Oncology presently has a consensus rating of “Buy” and a consensus price target of $80.02.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit